AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$OBIO

Sherman Darren sold $95K of OBIO

Sherman Darren (See Remarks) sold 15,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $6.36 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sherman Darren
Published Oct 2, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OBIO
Neutral
medium confidence
Mentioned
$OBIO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OBIONeutralLow
01

Why it matters

The transaction is modest in size and unlikely to move the stock significantly, but it adds transparency for investors monitoring insider activity.

02

Market read

A routine insider sale with limited market impact; useful for compliance monitoring but low trading relevance.

03

What to watch

Insider holds >1M shares post‑sale, indicating continued confidence.

Relevance 2/10Novelty 2/10Timing: after‑hours filing today

Background

SEC Form 4 filing provides the first public disclosure of the insider's share sale.

Company-level read

Ticker impact

$OBIONeutralMedium confidence
Context

Form 4 disclosed Officer/Direc­tor Sherman Darren sold 15,000 shares at $6.36, reducing his stake to 1,119,402 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

Sale size (~$95k) is modest for a micro‑cap; no broader catalyst, so impact is limited.

Market effects

Sector

Minimal; biotech sector not affected by a single small insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine liquidity need, not a negative signal.

Key entities

  • Company
    Orchestra BioMed Holdings, Inc.

    Biotech firm listed on NASDAQ under ticker OBIO.

  • Insider
    Sherman Darren

    Officer and Director of Orchestra BioMed Holdings.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OBIO insider trading history →

Related articles

$OBIOMed

H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment

H.C. Wainwright reiterated a Buy rating and $10.00 price target for Orchestra BioMed (OBIO) after its hypertension trial completed enrollment. The stock trades at $5.95, with a 119.56% return over the past year. The BACKBEAT trial, conducted with Medtronic, aims to treat uncontrolled hypertension in pacemaker patients. Orchestra plans to submit results for regulatory review in 2027. BTIG also upgraded OBIO to Buy with a $10 target.

investing.com